SCHEMBL4672153

SCHEMBL4672153

O=C(O)C(O)=CC(=O)c1cocc1Cc1ccccc1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 3/20 0.35
GPR52 Q9Y2T5 1/20 0.35
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
ABL1 P00519 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
AR P10275 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672147 1.00 PTPN1 (0.39) PTPN1MEN1KMT2ARXFP1ALDH1A1
SCHEMBL4674761 0.83 PTPN1 (0.37) PTPN1GPR52TSHR
SCHEMBL4674762 0.83 PTPN1 (0.37) PTPN1GPR52TSHR
SCHEMBL4673288 0.80 PTPN1 (0.40) PTPN1MEN1KMT2ARXFP1ALDH1A1
SCHEMBL4672692 0.80 CTBP2 (0.34) KMT2AALDH1A1KDM4EHPGDMAPK1
SCHEMBL4673291 0.80 PTPN1 (0.40) PTPN1MEN1KMT2ARXFP1ALDH1A1
SCHEMBL4672693 0.80 CTBP2 (0.34) KMT2AALDH1A1KDM4EHPGDMAPK1
SCHEMBL4672983 0.80 HCAR2 (0.39) PTPN1GPR52RAB9A
SCHEMBL4672985 0.80 HCAR2 (0.39) PTPN1GPR52RAB9A
SCHEMBL4678288 0.79 PTPN1 (0.39) PTPN1MEN1KMT2ARXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTPN1 2715/4885MEN1 4663/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.